The global market for organ-on-chip is projected to have a CAGR of around 34.1% during the forecast period. Organs-on-chips (OoCs), also known as microphysiological systems (MPS) or ‘tissue chips’ has the potential to be informative at multiple stages of the drug discovery and development process. These innovative devices could provide insights into normal human organ function and disease pathophysiology, as well as more accurately predict the safety and efficacy of investigational drugs in humans. The major driver for the market includes the development of human tissue chips for improvement in drug discovery and improvement in the prediction of organ toxicity liabilities. Apart from this, the product launches and advancement in technology, and initiatives to promote awareness among populations are the other factors that are driving the growth of the market. For instance, in October 2020, BioVox started an awareness program for Dutch startup Bi/ond to raise awareness by promoting organ-on-chip initiatives. Through this awareness initiative, BioVocx aims to promote the adoption of Organ-on-Chip technology to improve in vitro research models and reduce animal testing. However, the high cost of organ-on-chip models and technical difficulties linked with organ-on-chip technology acts as a barrier to the growth of the market. Whereas the demand for personalized cancer treatment and growing research and funding for organ-on-chip models will create an ample opportunity for the market during the forecast period.

COVID-19 Impact on Organ-on-Chip market: The organ-on-chip market is positively affected by the outbreak of the COVID-19 pandemic since December 2019. The key industry application of organ-on-chip includes drug discovery, toxicology research, and others that rely on the region such as North America and Asia-Pacific. The outbreak of COVID-19 in the major economies of these regions such as the US and China, Japan has positively impacted the market growth. To curb the spreading of COIVID-19 among the world’s population the scientists and researchers have been using organ-on-chips for drug discovery for the vaccination and to understand immune responses against SARS-CoV-2. In Oct 2020, The Food and Drug Administration had used organ-on-chip models to test mechanisms for preventing COVID-19 infections, and other processes. The FDA used Emulate Inc’s organ-on-chip models for this process under a cooperative research agreement. During the COVID-19 pandemic, the use of lung-on-chips was increased for the research and developments of drugs to recover the lung infection caused by the virus. These factors affected the growth of the market positively. 

Segmental Outlook  

The global organ-on-chip market is segmented based on type, application, and end-user. On the basis of organ type, the organ-on-chip market is segmented into lung-on-chip, heart-on-chip, kidney-on-chip, and others. Among these types, the heart-on-chip type has a higher potential to grow during the forecast period. Due to the rising prevalence of cardiovascular disease (CVD), heart-on-chip are microdevices are primarily used for heart disease research, cardiotoxicity screening, drug target discovery, and drug efficacy testing. Similarly, based on application, the market is further categorized into drug discovery, toxicology research, and others. Based on end-user, the market is divided into the pharmaceutical & biotechnology industry, academic & research institutes.

Global Organ-on-chip Market Share by Application, 2020 (%)

Drug discovery application holds the Major Share in the global organ-on-chip market 

Among application, the drug discovery segment projected to have the largest share in the market in 2020 and is expected to continue its dominance during the forecast period. The rising application of organ-on-chip devices in the drug development pipeline from early drug discovery to preclinical screening, testing, and translation of new drugs results in the growth of the market. Organ-on-chip in drug discovery reduces the drug failure rate. Many pharmaceutical companies have been searching for efficient drug discovery methods, Organ-on-a-Chip can provide them with cutting-edge technology that can emulate the physiological environment and functionality of human organs on a chip for disease modelling and drug testing. Thus, the use of organ-on-chip in drug discovery application to discover an effective solution to eliminating the effect of the disease can drive the demand for these chips, that will further drive the overall market growth. 

Regional Outlook 

Geographically, the global organ-on-chip market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, ASEAN and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is anticipated to witness a significant growth rate during the forecast period due to growing awareness of and government initiatives for the adoption of innovative healthcare technologies and the development of organ modular platforms. The emerging economies such as China, Japan, India, and South Korea are also expecting to contribute to the growth of the organ-on-chip market in the region. The rise in disposable income, the growing number of clinical trials, and the rising investment in R&D activities are expected to propel the market growth.

Global Organ-on-chip Market Growth, by Region 2021-2027

North America projected to Dominates the Organ-on-chip Market

Geographically, North America is projected to dominate the organ-on-chip market and is estimated to maintain its dominance with a significant CAGR during the forecast period. The factors propelling the growth of the organ-on-chip market in the region include rising investment by public and private sectors, increasing toxicological testing of chemicals on the different types of organ cells, and technological advancement and their rapid adoption. Besides, the presence of pharmaceutical companies and key market players, availability of advanced organ-on-chip models, government support in form of funding, and awareness initiatives to promote organ-on-chip adoption also fueling the market growth.

Market Players Outlook

The key players in the organ-on-chip market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are MIMETAS B.V., BiomimX SRL, InSphero AG, Emulate, Inc., Hurel Corp., CN Bio Innovations, Ascendance Biotechnology, Inc., Nortis Inc., TissUse GmbH, Organovo Holdings, Inc, TARA Biosystems, Inc., among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, partnership collaboration, and geographical expansions so on. For instance, in August 2020, InSphero AG and ETH Zurich Bio Engineering Laboratory had a partnership collaboration for the commercialization of InSphero’s Akura Flow organ-on-chip platform. It is a MPS designed to integrate 3D spheroid models for preclinical drug efficacy and toxicity testing applications under single- and multi-tissue organ networks.

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global organ-on-chip market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.